Mitapivat
ATC B06AX04 · 4 markets · 17 records
GB 6 records · 3 strengths
US 5 records · 4 strengths
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 PYRUKYND
| Strength / form / release | US | GB | EU |
|---|---|---|---|
| 50 mg tablet | PYRUKYND | PYRUKYND Pyrukynd 20mg/5mg 2 week taper pack | |
| 20 mg tablet | PYRUKYND | PYRUKYND Pyrukynd 20mg/5mg 2 week taper pack | |
| 5 mg tablet | PYRUKYND | PYRUKYND Pyrukynd 5mg 1 week taper pack | |
| 100 mg tablet | AQVESME | ||
unknown | PYRUKYND |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
1 more strength/form rows are recorded only in EU and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en EU que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 EU 有记录（未在本表显示）。 另有 1 個規格/劑型僅在 EU 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.